Streetbeat News

Price Targets

DRI

Wells Fargo analyst Zachary Fadem maintains an Equal-Weight rating on Darden Restaurants and raises the price target from $160 to $165.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:38 pm

GLW

Oppenheimer analyst Martin Yang maintains an Outperform rating on Corning (NYSE:GLW) and raises the price target from $47 to $51.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:35 pm

SEAT

Citigroup analyst Jason Bazinet maintains a Buy rating on Vivid Seats (NASDAQ:SEAT) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:31 pm

APLS

Mizuho analyst Graig Suvannavejh has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) while lowering the price target from $42 to $39.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:30 pm

NJR

Mizuho analyst Gabriel Moreen maintains a Neutral rating on New Jersey Resources (NYSE:NJR) and raises the price target from $45 to $47.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:28 pm

COF

Citigroup analyst Keith Horowitz has initiated coverage on Capital One Financial (NYSE:COF) with a Buy rating and set a price target of $190.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:27 pm

UPST

Mizuho analyst Dan Dolev has maintained an 'Outperform' rating on Upstart Holdings (NASDAQ:UPST) and raised the price target from $33 to $48.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:26 pm

ZVRA

HC Wainwright & Co. has maintained a Buy rating on Zevra Therapeutics and raised the price target from $18 to $20, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:26 pm

LRCX

Mizuho analyst Vijay Rakesh maintains an Outperform rating on Lam Research but lowers the price target from $1050 to $950.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:24 pm

ITCI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $130.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:24 pm